Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Taiwanese (TAIEX) Pharma Industry Analysis

UpdatedJul 12, 2026
DataAggregated Company Financials
Companies59
  • 7D1.2%
  • 3M0.9%
  • 1Y-7.4%
  • YTD-14.8%

In the last week, the Pharma industry is up 1.2%, with Caliway Biopharmaceuticals up 7.8%. However, the industry is down 7.4% over the past year. As for the next few years, earnings are expected to grow by 86% per annum.

Industry Valuation and Performance

Has the Taiwanese Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 12 Jul 2026NT$634.4bNT$123.1bNT$18.9b18.4x33.5x5.2x
Tue, 09 Jun 2026NT$579.8bNT$123.1bNT$19.0b18.2x30.5x4.7x
Thu, 07 May 2026NT$615.4bNT$119.4bNT$20.6b15.1x29.9x5.2x
Sat, 04 Apr 2026NT$609.8bNT$119.2bNT$20.7b15x29.4x5.1x
Mon, 02 Mar 2026NT$762.9bNT$119.4bNT$12.4b17x61.4x6.4x
Wed, 28 Jan 2026NT$812.6bNT$119.3bNT$12.4b17.8x65.4x6.8x
Fri, 26 Dec 2025NT$742.3bNT$118.0bNT$12.3b16.7x60.3x6.3x
Sun, 23 Nov 2025NT$675.9bNT$118.0bNT$12.1b16.1x55.8x5.7x
Tue, 21 Oct 2025NT$794.0bNT$118.3bNT$9.6b15.6x82.6x6.7x
Thu, 18 Sep 2025NT$829.7bNT$118.4bNT$10.2b16.4x81.2x7x
Sat, 16 Aug 2025NT$724.6bNT$117.7bNT$11.5b18.9x63x6.2x
Mon, 14 Jul 2025NT$655.0bNT$116.0bNT$14.3b18.5x45.8x5.6x
Wed, 11 Jun 2025NT$625.2bNT$115.9bNT$14.3b19.3x43.8x5.4x
Fri, 09 May 2025NT$567.7bNT$113.4bNT$10.5b20.3x54.2x5x
Sun, 06 Apr 2025NT$596.0bNT$112.8bNT$10.8b18.3x55.1x5.3x
Tue, 04 Mar 2025NT$672.4bNT$109.3bNT$11.4b23.4x58.8x6.2x
Thu, 30 Jan 2025NT$612.0bNT$109.3bNT$11.4b21.7x53.5x5.6x
Sat, 28 Dec 2024NT$599.4bNT$109.3bNT$11.4b22.2x52.4x5.5x
Mon, 25 Nov 2024NT$629.2bNT$109.2bNT$11.5b23x54.8x5.8x
Wed, 23 Oct 2024NT$625.9bNT$104.7bNT$8.9b26.8x70x6x
Fri, 20 Sep 2024NT$630.3bNT$104.7bNT$8.9b25.1x70.5x6x
Sun, 18 Aug 2024NT$659.5bNT$104.7bNT$9.0b27.9x73.5x6.3x
Tue, 16 Jul 2024NT$699.7bNT$100.5bNT$6.8b32.3x102.5x7x
Thu, 13 Jun 2024NT$638.8bNT$100.4bNT$7.1b30.4x89.4x6.4x
Sat, 11 May 2024NT$613.8bNT$101.9bNT$9.4b27x65.6x6x
Mon, 08 Apr 2024NT$700.0bNT$101.5bNT$9.2b26.7x76x6.9x
Wed, 06 Mar 2024NT$659.1bNT$102.0bNT$8.7b24.3x76.2x6.5x
Fri, 02 Feb 2024NT$595.8bNT$101.9bNT$7.8b23.8x76.5x5.8x
Sun, 31 Dec 2023NT$580.1bNT$101.9bNT$7.8b23.9x74.4x5.7x
Tue, 28 Nov 2023NT$581.3bNT$101.6bNT$7.7b24x76x5.7x
Thu, 26 Oct 2023NT$540.4bNT$101.7bNT$9.6b20.8x56.2x5.3x
Sat, 23 Sep 2023NT$544.5bNT$101.7bNT$9.6b22x56.6x5.4x
Mon, 21 Aug 2023NT$543.8bNT$101.7bNT$9.6b21.5x56.4x5.3x
Wed, 19 Jul 2023NT$575.1bNT$98.7bNT$10.1b16.9x57.1x5.8x
Price to Earnings Ratio

57.1x


Total Market Cap: NT$575.1bTotal Earnings: NT$10.1bTotal Revenue: NT$98.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Taiwanese Pharma Industry Price to Earnings3Y Average 61.8x202420252026
Current Industry PE
  • Investors are pessimistic on the Taiwanese Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 33.5x which is lower than its 3-year average PE of 61.8x.
  • The 3-year average PS ratio of 5.9x is higher than the industry's current PS ratio of 5.2x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 23% per year over the last three years.
  • Revenues for these companies have grown 7.6% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Taiwanese Healthcare industry?

TW Market-3.15%
Healthcare2.62%
Pharma1.16%
Pharma1.16%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
6919 Caliway BiopharmaceuticalsNT$107.507.8%
+NT$12.1b		-11.5%PS4398.4x
1795 Lotus PharmaceuticalNT$204.002.3%
+NT$1.2b		-5.1%PE13.9x
4114 Synmosa BiopharmaNT$33.354.9%
+NT$774.6m		-2.2%PE20.7x
6467 Taho PharmaceuticalsNT$116.507.4%
+NT$419.0m		138.2%PS1125.5x
4166 Orient PharmaNT$27.257.3%
+NT$412.6m		-24.3%PE30.9x

Latest News

6472
NT$426.00
Bora Pharmaceuticals
7D
-3.1%
1Y
-38.6%
Narrative Update • Jul 09

6472: Future Earnings Assumptions And Lower P/E Will Shape Fair Value

Analysts have revised their price target on Bora Pharmaceuticals from NT$530 to NT$430, citing updated expectations for revenue growth, profit margins, and a lower future P/E assumption in their valuation work. What's in the News for Bora Pharmaceuticals Analysts cut their Bora Pharmaceuticals price target from NT$530 to NT$430, reflecting updated assumptions on revenue, profit margins, and future P/E multiples.
4127
NT$74.00
Tien Liang BioTech
7D
6.0%
1Y
108.2%
4114
NT$33.35
Synmosa Biopharma
7D
4.9%
1Y
-2.2%
1795
NT$204.00
Lotus Pharmaceutical
7D
2.3%
1Y
-5.1%
Narrative Update • Jun 25

1795: Complex Generics Expansion And Lower Margins Will Shape Future P E Outlook

Analysts have revised their fair value estimate for Lotus Pharmaceutical to NT$200.0 from NT$311, reflecting updated assumptions for the discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News Lotus Pharmaceutical announced the global launch of its Nintedanib soft gel capsules in 100mg and 150mg strengths as part of its specialty and complex generics portfolio.
6620
NT$99.50
Handa Pharmaceuticals
7D
-2.9%
1Y
19.9%
6919
NT$107.50
Caliway Biopharmaceuticals
7D
7.8%
1Y
-11.5%
6467
NT$116.50
Taho Pharmaceuticals
7D
7.4%
1Y
138.2%
4166
NT$27.25
Orient Pharma
7D
7.3%
1Y
-24.3%
4123
NT$38.95
Center Laboratories
7D
-1.8%
1Y
8.3%
4743
NT$54.20
Oneness Biotech
7D
-5.4%
1Y
-11.4%
6535
NT$100.50
Lumosa Therapeutics
7D
-6.5%
1Y
-28.2%
6586
NT$122.00
CHO Pharma
7D
-4.7%
1Y
199.0%
7860
NT$74.90
TEH SENG Pharmaceutical Mfg
7D
18.9%
1Y
n/a
6785
NT$117.00
Alar Pharmaceuticals
7D
-5.3%
1Y
-19.0%
6676
NT$14.65
Sunny Pharmtech
7D
14.9%
1Y
7.3%
7878
NT$229.00
Pharmasaga
7D
-10.0%
1Y
n/a